5 results about "Primary cancer" patented technology

The present invention relates to a composition for the prevention or treatment of metastatic cancer, capable of inducing an abscopal effect, which is a systemic anticancer effect, in combination with radiotherapy to treat metastatic cancer that has spread from a primary cancer, wherein, by having confirmed that, upon radiotherapy in which a primary cancer site was irradiated with a low dose of radiation, the abscopal effect, which is a systemic anticancer effect, did not appear, whereas, when type 1 interferon was administered in combination with low-dose radiation to the primary cancer site, an anticancer effect appears even in non-radiated metastatic cancer sites, a composition comprising type 1 interferon is provided as a therapeutic agent or adjuvant for the treatment of metastatic cancer, which induces a systemic anticancer effect upon low-dose radiotherapy.

The present disclosure relates to an apparatus and a method for providing information for diagnosing micro-residual diseases through quantification of single-nucleotide variants in cfDNA. The apparatus according to the present disclosure comprises: a memory in which at least one process for performing an operation for providing information for diagnosing micro-residual diseases is stored; and a processor for performing an operation according to the process, wherein the processor analyzes WGS of patient-derived cancer tissues using two or more pieces of somatic variant analysis software to obtain data on the positions of consensus single-nucleotide variants commonly identified in primary cancer samples, matches reference sequences at the positions of the single-nucleotide variants with cfDNA WGS of the patient to obtain supporting reads matching in which the variants match in overlapping regions of paired reads, filters the obtained supporting reads on the basis of predetermined conditions, and generates probability data related to micro-residual diseases on the basis of the filtered supporting reads.

The present application is directed to a combination therapy comprising a thyroid hormone receptor beta-1 (TKβ) agonist, and a primary cancer therapeutic. Methods of treating cancer and inducing differentiation in a population of cancer cells are also disclosed.

The application belongs to the technical field of biotechnology, and particularly discloses a method for extracting primary cancer-associated fibroblasts from renal clear cell carcinoma tissue. The method comprises the following steps: treating fresh renal clear cell carcinoma tissue at 0-4 DEG C, and only retaining a region rich in tumor cells and interstitial mixed; low-speed shearing the region rich in tumor cells and interstitial mixed into fragments with a volume of 1-3 mm 3 ; placing the fragments in a collagenase I solution, collecting cell precipitates after digestion is completed; inoculating the cell precipitates into a first culture medium, and replacing the fresh first culture medium every day within the first 3 days after inoculation, and then replacing the first culture medium every 2-3 days. The method overcomes the problems of low cell adhesion rate, serious contamination, low cell activity and low purity of the conventional extraction technology of primary cancer-associated fibroblasts when applied to renal clear cell carcinoma tissue, and can stably obtain primary cancer-associated fibroblasts with high purity and high survival rate within 7-10 days.

A cultivation method for simulated microgravity-induced reprogramming of primary cancer cells and related culture media and reagents are in the field of biotechnology. A multi-directional G-force generator is used to simulate a 10−3 g microgravity environment, inducing reprogramming of cancer / cancer-adjacent tissue cells derived from patients, maintaining stemness of primary cell populations, and achieving rapid, long-term, high-fidelity cultivation of tissue cells from patients. Using this cultivation method, 106 cells can be obtained within 7 days from a 1 mm3 tissue block acquired during surgery for drug screening. Specially formulated culture media, washing solutions, and digestion solutions are also provided, effectively solving problems of contamination susceptibility and difficult digestion of clinical samples. The established cancer cell models maintain highly similar genetic characteristics to the original tissue and can reflect differences in drug sensitivity between different patients, providing a powerful tool for precision cancer treatment.